MOTS-c

MOTS-c (mitochondrial ORF of the 12S rRNA type-c) is a mitochondrial-derived peptide that has garnered significant attention in metabolic research. This mitochondrial peptide operates through activation of the AMPK pathway, a crucial cellular energy sensor that regulates metabolic processes. In research models, MOTS-c demonstrates the ability to enhance glucose uptake and promote fatty acid oxidation, fundamental processes in cellular energy metabolism. Studies indicate that this mitochondrial peptide modulates the expression of genes involved in metabolism and stress response pathways, whilst promoting mitochondrial biogenesis and function. Research has shown that MOTS-c can improve insulin sensitivity in laboratory studies, suggesting potential applications in metabolic research. Additionally, studies indicate enhanced exercise capacity in research models, likely through improved mitochondrial function and energy expenditure mechanisms. The peptide's role in promoting mitochondrial biogenesis represents a particularly interesting area of research, as mitochondrial dysfunction is implicated in various age-related conditions. Research models have demonstrated that MOTS-c supports healthy aging processes through its metabolic regulatory effects. Current evidence is graded as B, with preliminary human trials indicating improvements in metabolic markers and exercise performance. However, researchers note that larger and more comprehensive studies are needed to fully confirm these effects and understand long-term implications. The compound is classified as FDA Category 2, with reclassification to Category 1 expected by February 2026, reflecting evolving regulatory perspectives on mitochondrial peptides in research applications.